Van Campenhout, Raf
De Groof, Timo W. M.
Kadam, Prashant
Kwak, Brenda R.
Muyldermans, Serge
Devoogdt, Nick
Vinken, Mathieu
Funding for this research was provided by:
Lead Agency grant of the Research Foundation Flanders-Belgium and the Swiss National Science Foundation (310030E-176050)
Strategic Research Program SRP50
European Research Council (Proof-of-Concept grant 861913)
European Future and Emerging Technologies program (grant 858014)
Research Foundation Flanders-Belgium (grants G012318N, G020018N and G0F7219N)
Methusalem program of the Flemish Government
University Hospital of the Vrije Universiteit Brussel-Belgium
Article History
Received: 26 May 2023
Accepted: 29 September 2023
First Online: 11 October 2023
Declarations
:
: Protocols to generate Panx1-targeting nanobodies, to examine the in vivo biodistribution of Panx1-targeting nanobodies and to study anti-inflammatory effects of Panx1-targeting nanobodies have been approved by the local Ethical Committee of the Vrije Universiteit Brussel-Belgium (project numbers 16-601-1, 21-210-1 and 20-210-8).
: Not applicable.
: R.V.C., T.D.G., N.D. and M.V. are co-inventonrs on a pending EU patent application EP23158621, which covers the use of Panx1-targeting nanobodies. The remaining authors declare no competing interests.